Literature DB >> 8402668

High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.

M Furihata1, K Inoue, Y Ohtsuki, H Hashimoto, N Terao, Y Fujita.   

Abstract

Ninety Japanese patients with transitional cell carcinoma of the urinary bladder were investigated for tumor incorporation of DNA for high-risk human papillomavirus (HPV) types 16, 18, and 33 by in situ hybridization with biotinylated DNA probes. In addition, immunohistochemical analysis of p53 protein expression was performed with an antibody to p53 protein. Twenty-eight tumors were positive for HPV DNA, and multiple HPV infection was detected in 17 cases. Positive nuclear staining of cancer cells by the antibody to p53 protein was detected in 32 cases. DNA for HPV 16, 18, and/or 33 and the overexpression of p53 protein were simultaneously observed in 6 tumors by using a mirror section method. The overexpression of p53 protein was frequently detected in invasive and nonpapillary tumors (P < 0.05) and in high grade tumors (P < 0.05). In contrast, HPV infection was more common in noninvasive and papillary tumors (P < 0.01). The patients with tumors positive for HPV DNA and/or p53 antibody had a significantly worse survival rate (P < 0.05). These results suggest that HPV infection or overexpression of p53 protein may be related to tumor behavior and may indicate a relatively poor prognosis in patients with transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402668

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers.

Authors:  Ioannis N Mammas; George Sourvinos; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-07-18       Impact factor: 3.201

2.  The analysis of human papillomavirus DNA in penile cancer tissue by in situ hybridization.

Authors:  Daiji Takamoto; Takashi Kawahara; Jun Kasuga; Takeshi Sasaki; Masahiro Yao; Yasushi Yumura; Hiroji Uemura
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

3.  Human papillomavirus and schistosomiasis associated bladder cancer.

Authors:  K Cooper; Z Haffajee; L Taylor
Journal:  Mol Pathol       Date:  1997-06

4.  Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation.

Authors:  C De Gaetani; G Ferrari; E Righi; S Bettelli; M Migaldi; P Ferrari; G P Trentini
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

5.  HPViewer: sensitive and specific genotyping of human papillomavirus in metagenomic DNA.

Authors:  Yuhan Hao; Liying Yang; Antonio Galvao Neto; Milan R Amin; Dervla Kelly; Stuart M Brown; Ryan C Branski; Zhiheng Pei
Journal:  Bioinformatics       Date:  2018-06-15       Impact factor: 6.937

6.  Role of human papillomavirus in the development of urothelial carcinoma.

Authors:  Dilek Yavuzer; Nimet Karadayi; Taflan Salepci; Huseyin Baloglu; Ahmet Bilici; Dilek Sakirahmet
Journal:  Med Oncol       Date:  2010-04-29       Impact factor: 3.064

7.  Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid.

Authors:  N Hayashi; M Furihata; Y Ohtsuki; H Ueno
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases.

Authors:  P Soriano; S Navarro; M Gil; A Llombart-Bosch
Journal:  Virchows Arch       Date:  2004-07-10       Impact factor: 4.064

9.  Introduction of wild-type p53 gene downregulates the expression of H-ras gene and suppresses the growth of bladder cancer cells.

Authors:  M Li; F L Gu; W B Li; Y S Song; A R Zhou; Y L Guo
Journal:  Urol Res       Date:  1995

Review 10.  Overexpression of p53 protein in human tumors.

Authors:  Keiji Inoue; Atsushi Kurabayashi; Taro Shuin; Yuji Ohtsuki; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2012-09-22       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.